Kyprolis Side Effects

Serious Side Effects of Kyprolis

Severe cardiac adverse reactions have been observed. Kyprolis may cause heart failure or ischemia, which is an insufficient blood supply to an organ.

Common Side Effects of Kyprolis

You may experience fatigue after a Kyprolis treatment.
Kyprolis may cause low blood cell count and thrombocytopenia (low platelet levels).
Trouble breathing, diarrhea, and fever have also been reported as side effects of taking Kyprolis.

Warnings & Recalls for Kyprolis

Kyprolis Warnings

Kyprolis may be toxic to a fetus. Do not take Kyprolis if you are pregnant or plan to become pregnant.
To prevent infusion reactions take dexamethasone.
Ensure that you are adequately hydrated to prevent Tumor Lysis Syndrome.
Stop Kyprolis doses if you experience symptoms of decreased liver function. Signs include yellowing of the skin or eyes (jaundice), darkened urine, and light colored stool.

Kyprolis Treatment and Use

Kyprolis | carfilzomib is an antineoplastic injection for patients with multiple myeloma. It is only approved for patients who have already received Velcade and immunomodulatory therapy. Patients should also exhibit a progression in their disease after 60 days of the last completed therapy before taking Kyprolis.

How does Kyprolis work?

Kyprolis is a proteasome inhibitor. Proteasomes are groups of cells that break down proteins. Kyprolis decreases proteasome activity in the blood and tissues, delaying the growth of tumors.

Kyprolis Dosage Information

Kyprolis is an injection which should be administered on two consecutive days a week for three weeks. Twelve days should separate treatment cycles. Treatment with Kyprolis is continued until toxicity levels become dangerous or the myeloma progresses.

Other Names for Kyprolis

Brand name:

Kyprolis

Generic name:

Carfilzomib